688062 Mabwell
- 23.23
- -0.07-0.30%
Mabwell News
Meiwei Biopharmaceutical voluntarily disclosed the announcement on the inclusion of 9MW2821 for the indication of urothelial carcinoma into breakthrough therapy drugs.
Announcement of Maiwei Bio's increase in credit and financing amount applications to financial institutions for the 2024 fiscal year.
The verification opinion on the change of part of the fundraising special account and the re-signing of the four-party regulatory agreement by Maiwei (Shanghai) biotechnology Co., Ltd., submitted by Haitong Securities Co., Ltd.
Announcement from Maiwei Biology regarding its wholly-owned subsidiary's signing of a licensing agreement with Runjia Pharmaceutical.
Announcement of resolutions of the 11th meeting of the second session of the supervisory board of Maiwei Biology.
Announcement on the change of the special account for raising funds and the re-signing of the quadrilateral supervision agreement by Maiwei Biology.
Maiwei Biological Investor Relations Activity Record (July 02, 2024)
Maiwei Biology Investor Relations Activity Record Form (July 01, 2024)
Record of Investor Relations Activities for Maiwei Biology (June 01, 2024)
Announcement of Maiwei Biology on the convening of the 2023 annual and first quarter of 2024 earnings briefing.
Announcement of resolutions from the second extraordinary shareholders' meeting of Maiwei Biotech in 2024.
Legal Opinion from Beijing Zhede (Shanghai) Law Firm regarding the 2024 Second Extraordinary General Meeting of Shareholders of Maui (Shanghai) Biotechnology Co., Ltd.
Maiwei Biotech Investor Relations Activity Record List (2024/05/01)
Notice of Maiwei Biotech on convening the 2nd Extraordinary General Meeting of Shareholders in 2024
Announcement of Resolutions of the 10th Meeting of the 2nd Supervisory Board of Maiwei Biotech
Announcement of Maiwei Biotech regarding the termination and re-provision of guarantees by the Company and its wholly-owned subsidiaries for wholly-owned subsidiaries
Maiwei Biotech's announcement on the resignation of independent directors, nomination of independent directors, and adjustment of members of the 2nd Board of Directors Special Committee
Haitong Securities Co., Ltd.'s inspection opinion on the termination and re-provision of guarantees for wholly-owned subsidiaries by Maiwei (Shanghai) Biotechnology Co., Ltd. and its wholly-owned subsidiaries
Maiwei Biotech Independent Director Candidate Statement and Commitment (Qin Zhengyu)
Maiwei Biotech Independent Director Nominee Statement and Commitment (Qin Zhengyu)
Analysis
Price Target
No Data
